Jonathan R Dillman1, Soudabeh Fazeli Dehkordy2, Ethan A Smith2, Michael A DiPietro2, Ramon Sanchez2, Vera DeMatos-Maillard3, Jeremy Adler3, Bin Zhang4, Andrew T Trout5. 1. Department of Radiology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave., ML5031, Cincinnati, OH, 45229-3039, USA. jonathan.dillman@cchmc.org. 2. Department of Radiology, Section of Pediatric Radiology, C. S. Mott Children's Hospital, University of Michigan Health System, Ann Arbor, MI, USA. 3. Department of Pediatrics, Division of Gastroenterology, C. S. Mott Children's Hospital, University of Michigan Health System, Ann Arbor, MI, USA. 4. Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. 5. Department of Radiology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave., ML5031, Cincinnati, OH, 45229-3039, USA.
Abstract
BACKGROUND: Little is known about changes in the imaging appearances of the bowel and mesentery over time in either pediatric or adult patients with newly diagnosed small bowel Crohn disease treated with anti-tumor necrosis factor-alpha (anti-TNF-α) therapy. OBJECTIVE: To define how bowel ultrasound findings change over time and correlate with laboratory inflammatory markers in children who have been newly diagnosed with pediatric small bowel Crohn disease and treated with infliximab. MATERIALS AND METHODS: We included 28 pediatric patients treated with infliximab for newly diagnosed ileal Crohn disease who underwent bowel sonography prior to medical therapy and at approximately 2 weeks, 1 month, 3 months and 6 months after treatment initiation; these patients also had laboratory testing at baseline, 1 month and 6 months. We used linear mixed models to compare mean results between visits and evaluate whether ultrasound measurements changed over time. We used Spearman rank correlation to assess bivariate relationships. RESULTS: Mean subject age was 15.3±2.2 years; 11 subjects were girls (39%). We observed decreases in mean length of disease involvement (12.0±5.4 vs. 9.1±5.3 cm, P=0.02), maximum bowel wall thickness (5.6±1.8 vs. 4.7±1.7 mm, P=0.02), bowel wall color Doppler signal (1.7±0.9 vs. 1.2±0.8, P=0.002) and mesenteric color Doppler signal (1.1±0.9 vs. 0.6±0.6, P=0.005) at approximately 2 weeks following the initiation of infliximab compared to baseline. All laboratory inflammatory markers decreased at 1 month (P-values<0.0001). There was strong correlation between bowel wall color Doppler signal and fecal calprotectin (ρ=0.710; P<0.0001). Linear mixed models confirmed that maximum bowel wall thickness (P=0.04), length of disease involvement (P=0.0002) and bowel wall color Doppler signal (P<0.0001) change over time in response to infliximab, when adjusted for age, sex, azathioprine therapy, scanning radiologist and baseline short pediatric Crohn's disease activity index score. CONCLUSION: The ultrasound appearance of the bowel changes as early as 2 weeks after the initiation of infliximab therapy. There is strong correlation between bowel wall color Doppler signal and fecal calprotectin.
BACKGROUND: Little is known about changes in the imaging appearances of the bowel and mesentery over time in either pediatric or adult patients with newly diagnosed small bowel Crohn disease treated with anti-tumor necrosis factor-alpha (anti-TNF-α) therapy. OBJECTIVE: To define how bowel ultrasound findings change over time and correlate with laboratory inflammatory markers in children who have been newly diagnosed with pediatric small bowel Crohn disease and treated with infliximab. MATERIALS AND METHODS: We included 28 pediatric patients treated with infliximab for newly diagnosed ileal Crohn disease who underwent bowel sonography prior to medical therapy and at approximately 2 weeks, 1 month, 3 months and 6 months after treatment initiation; these patients also had laboratory testing at baseline, 1 month and 6 months. We used linear mixed models to compare mean results between visits and evaluate whether ultrasound measurements changed over time. We used Spearman rank correlation to assess bivariate relationships. RESULTS: Mean subject age was 15.3±2.2 years; 11 subjects were girls (39%). We observed decreases in mean length of disease involvement (12.0±5.4 vs. 9.1±5.3 cm, P=0.02), maximum bowel wall thickness (5.6±1.8 vs. 4.7±1.7 mm, P=0.02), bowel wall color Doppler signal (1.7±0.9 vs. 1.2±0.8, P=0.002) and mesenteric color Doppler signal (1.1±0.9 vs. 0.6±0.6, P=0.005) at approximately 2 weeks following the initiation of infliximab compared to baseline. All laboratory inflammatory markers decreased at 1 month (P-values<0.0001). There was strong correlation between bowel wall color Doppler signal and fecal calprotectin (ρ=0.710; P<0.0001). Linear mixed models confirmed that maximum bowel wall thickness (P=0.04), length of disease involvement (P=0.0002) and bowel wall color Doppler signal (P<0.0001) change over time in response to infliximab, when adjusted for age, sex, azathioprine therapy, scanning radiologist and baseline short pediatric Crohn's disease activity index score. CONCLUSION: The ultrasound appearance of the bowel changes as early as 2 weeks after the initiation of infliximab therapy. There is strong correlation between bowel wall color Doppler signal and fecal calprotectin.
Authors: Matthew P Moy; Jess L Kaplan; Christopher J Moran; Harland S Winter; Michael S Gee Journal: AJR Am J Roentgenol Date: 2016-06-28 Impact factor: 3.959
Authors: Petter Malmborg; Lena Grahnquist; Maja Ideström; Johan Lindholm; Ragnar Befrits; Jan Björk; Scott Montgomery; Hans Hildebrand Journal: Inflamm Bowel Dis Date: 2015-05 Impact factor: 5.325
Authors: Victoria Grossi; Trudy Lerer; Anne Griffiths; Neal LeLeiko; Jose Cabrera; Anthony Otley; James Rick; David Mack; Athos Bousvaros; Joel Rosh; Andrew Grossman; Shehzaad Saeed; Marsha Kay; Brendan Boyle; Maria Oliva-Hemker; David Keljo; Marian Pfefferkorn; William Faubion; Michael D Kappelman; Boris Sudel; James Markowitz; Jeffrey S Hyams Journal: Clin Gastroenterol Hepatol Date: 2015-04-21 Impact factor: 11.382
Authors: Jonathan R Dillman; Ethan A Smith; Ramon Sanchez; Jeremy Adler; Soudabeh Fazeli; Bin Zhang; Matthew S Davenport Journal: AJR Am J Roentgenol Date: 2016-08-09 Impact factor: 3.959
Authors: Elsa A van Wassenaer; Floris A E de Voogd; Rick R van Rijn; Johanna H van Der Lee; Merit M Tabbers; Faridi S van Etten-Jamaludin; Krisztina B Gecse; Angelika Kindermann; Tim G J De Meij; Geert R D'haens; Marc A Benninga; Bart G P Koot Journal: J Crohns Colitis Date: 2019-12-10 Impact factor: 9.071
Authors: Johan F K F Ilvemark; Tawnya Hansen; Thomas M Goodsall; Jakob B Seidelin; Heba Al-Farhan; Mariangela Allocca; Jakob Begun; Robert V Bryant; Dan Carter; Britt Christensen; Marla C Dubinsky; Krisztina B Gecse; Torsten Kucharzik; Cathy Lu; Christian Maaser; Giovanni Maconi; Kim Nylund; Carolina Palmela; Stephanie R Wilson; Kerri Novak; Rune Wilkens Journal: J Crohns Colitis Date: 2022-05-10 Impact factor: 10.020
Authors: Christian Maaser; Frauke Petersen; Ulf Helwig; Imma Fischer; Alexander Roessler; Stefan Rath; Dorothee Lang; Torsten Kucharzik Journal: Gut Date: 2019-12-20 Impact factor: 23.059
Authors: Elsa A van Wassenaer; Floris A E de Voogd; Rick R van Rijn; Johanna H van der Lee; Merit M Tabbers; Faridi S van Etten-Jamaludin; Angelika Kindermann; Tim G J de Meij; K B Gecse; Geert R D'Haens; Marc A Benninga; Bart G P Koot Journal: Pediatr Radiol Date: 2019-12-14
Authors: Elsa A van Wassenaer; Marc A Benninga; Johan L van Limbergen; Geert R D'Haens; Anne M Griffiths; Bart G P Koot Journal: Inflamm Bowel Dis Date: 2022-05-04 Impact factor: 5.325
Authors: José María Paredes; Tomás Ripollés; Ángela Algarra; Rafael Diaz; Nadia Moreno; Patricia Latorre; María Jesús Martínez; Pilar Llopis; Antonio López; Eduardo Moreno-Osset Journal: Intest Res Date: 2022-03-15